Immunohistochemical evidence of neuronal and glial differentiation in retinoblastoma

Ke-Ping Xu, Shiang-Lian Liu, Chuo Ni

Abstract

Background—The study sought to investigate the histogenesis of retinoblastoma. Methods—One hundred specimens of retinoblastomas were examined along with those of 18 astrocytic gliomas and 15 medulloblastomas to compare similarities of glial differentiation in retinoblastoma and the two types of brain tumour. Employing avidin-biotin immunoperoxidase technique, antibodies were applied against neuron specific enolase (NSE), glial fibrillary acidic protein (GFAP), and S-100 protein (S-100).

Results—Most rosettes and fleurettes, and some undifferentiated cells in retinoblastomas were NSE positive, but GFAP and S-100 negative. GFAP and S-100 positive cells in retinoblastomas were detected mostly in well differentiated glial cells which were interpreted as reactive or non-neoplastic cells. Some of the GFAP and S-100 positive cells in retinoblastomas were defined as tumour cells that resembled neoplastic astrocytes in astrocytic gliomas and medulloblastomas.

Conclusion—Retinoblastoma may arise from primitive bipotential or multi-potential cells capable of neuronal and glial differentiation.

Retinoblastoma is the most common primary intraocular neoplasm in children. Its histogenesis has been disputed for more than a century. The view that retinoblastoma was a glioma of the retina was first proposed by Virchow in 1864. Flexner subsequently described rosettes as the characteristic of a well differentiated form of the tumour, suggesting that retinoblastoma was a neurocytoma of the retina. However, Bailey and Cushing considered the undifferentiated retinoblastic cells to be the progenitor of the tumour. Previous electron microscopic study by Tso and associates demonstrated that retinoblastoma cells shared many features with normal retinal photoreceptors, indicative of their neuronal origin. The advent of immunohistochemistry makes it possible to detect neuronal and glial elements in situ. Immunohistochemical studies have proved that retinoblastoma may arise from neuronal or neuroectodermal cells or from primitive stem cells devoid of any glial differentiation. Astrocytes in the tumour were interpreted as being either reactive, in response to tumour growth and proliferation, or neoplastic, based on their distribution pattern and cytological features. Nevertheless, no agreement has been reached as to the existence of neoplastic glial cells in retinoblastoma.

In this histogenetic study we examined retinoblastomas along with astrocytic gliomas and cerebellar medulloblastomas in order to compare glial differentiation in retinoblastoma and the two types of brain tumour. We also determined relations between clinicopathological features and the expression of neuronal markers in a large retinoblastoma series.

Materials and methods

Formalin fixed and paraaffin embedded tissues of 100 enucleated retinoblastomas, 18 astrocytic gliomas, and 15 medulloblastomas were randomly selected. Immunohistochemical staining was carried out by the avidin-biotin peroxidase complex method (ABC) to detect the presence of neuron specific enolase (NSE), glial fibrillary acidic protein (GFAP), and S-100 protein (S-100). Sections of 5 µm were cut and mounted on clean gelatin coated slides. They were routinely deparaaffinised in xylene and hydrated in an ethanol series. Each step was followed by washing with TRIS buffered saline (TBS, pH 7-6, 0.05 M). Sections, except those stained for NSE, were treated with 0.05% trypsin for 20 minutes, the resulting digestion unmasking the antigen before immunohistochemistry. They were then incubated with 1% normal horse serum for 20 minutes to quench endogenous peroxidase activity. Anti-NSE (A589, Dako, CA, USA) and anti-GFAP (2334, Dako), as primary antisera, were diluted 1:1000 with TBS, while anti-S-100 (K524, Dako) gave best results in a 1:5 dilution. Primary antibody incubation was carried out in a moist chamber at 4°C overnight. Sections were then reacted with secondary antisera (biotinylated goat anti-rabbit IgG, 1:200, Vector Laboratories, CA, USA) for 30 minutes and subsequently treated with the avidin-biotinylated peroxidase complex (1:100, Vector Laboratories) for 60 minutes. Sites of peroxidase activity were visualised by incubation with 0.3% hydrogen peroxide and freshly prepared 3, 3 diaminobenzidine in TRIS buffer to generate the colour reaction. Slides were counterstained with haematoxylin and mounted after dehydration through graded ethanol and xylene.

Non-immune rabbit serum was introduced as a negative control to substitute anti-NSE, GFAP, or S-100 in equal dilution to the primary antisera. A portion of normal retina within some of the retinoblastomas was used as a positive internal control. Consecutive
sections of both normal eye bulb and normal brain served as further positive controls.

In evaluating the staining results, we concentrated on the morphology of the cells and differentiating of neoplastic from non-neoplastic positivity. The $x^2$ test was applied and a level of $p<0.05$ was accepted as of statistical significance.

Results
Table 1 lists the results of immunohistochemical staining of three types of tumours. In retinoblastomas NSE positive cells were neoplastic only, while GFAP or S-100 positive ones included both neoplastic and non-neoplastic cells. We found only GFAP or S-100 positive tumour cells in astrocytic gliomas, whereas there were both NSE and GFAP or S-100 positive in the tumour cells of medulloblastomas. Table 2 gives the expression of neuronal and glial markers in neoplastic cells of retinoblastomas.

Table 1  Neuron specific enolase (NSE), glial fibrillary acidic protein (GFAP), and S-100 protein (S-100) immunoreactivity in three types of tumours (%)

<table>
<thead>
<tr>
<th>Tumour</th>
<th>NSE</th>
<th>GFAP</th>
<th>S-100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinoblastoma</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td></td>
<td>NNC</td>
<td>NNC</td>
<td>NNC</td>
</tr>
<tr>
<td>Astrocytic glioma</td>
<td>2/100 (2)</td>
<td>2/18 (11-1)</td>
<td>1/18 (11-1)</td>
</tr>
<tr>
<td></td>
<td>77/100 (77)</td>
<td>2/18 (11-1)</td>
<td>1/18 (5-6)</td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td>2/70 (2 9)</td>
<td>4/15 (26-7)</td>
<td>2/15 (15)</td>
</tr>
<tr>
<td></td>
<td>91/15 (60)</td>
<td>3/15 (20)</td>
<td>3/15 (20)</td>
</tr>
</tbody>
</table>

NC=neoplastic cells; NNC=non-neoplastic cells. The ratio indicates the number of positive cases in the total cases studied.

NEURON SPECIFIC ENOLASE
With polyclonal antiserum against NSE, outer and inner segments of photoreceptor cells

![Figure 1](http://bjo.bmj.com/)  
**Figure 1** Neuron specific enolase (NSE) positive segments in the outer and inner nuclear layer, as well as ganglion cells of the normal retina (A). A portion of normal retina stained with NSE (arrows) can be found remaining in the tumour mass (B) (haematoxylin and eosin, bar indicates 100 μm).

Table 2  Expression of neuron specific enolase (NSE), glial fibrillary acidic protein (GFAP), and S-100 protein (S-100) in neoplastic cells of 100 retinoblastomas according to histopathological type

<table>
<thead>
<tr>
<th>Histopathological type</th>
<th>NSE (%)</th>
<th>GFAP (%)</th>
<th>S-100 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Differentiated</td>
<td>28/30 (93-3)</td>
<td>0/30 (0)</td>
<td>5/30 (16-7)</td>
</tr>
<tr>
<td>Undifferentiated</td>
<td>29/70 (41-4)</td>
<td>270 (2-9)</td>
<td>3/70 (4-3)</td>
</tr>
</tbody>
</table>

N=number of cases; ratio indicates the number of positive cases in the total cases studied.

GLIAL FIBRILLARY ACIDIC PROTEIN
In normal retina or part of the retina not invaded by tumour cells, GFAP positivity was encountered in glial cells of the ganglion layer, such as perivascular astrocytes and satellite glial cells, and in Muller's cells which extended through almost the entire thickness of the retina. The optic nerve contained numerous GFAP positive cells, and this reaction served as an internal positive control.

In two of 100 retinoblastomas (2%), we found some GFAP positive cells showing morphological similarity to the surrounding tumour cells, with a round hyperchromatic nucleus, scanty cytoplasm, and a few short thick processes (Fig 4A). The GFAP positive areas were distributed randomly throughout the undifferentiated areas of the tumour and were not associated with blood vessels. In some cases other GFAP positive cells were found surrounding blood vessels, with
In some astrocytic gliomas (16/18, 88.9%) and medulloblastomas (4/15, 26.7%), well differentiated cells exhibiting features of neoplasm were GFAP positive (Figs 4B and C, respectively), resembling those in retinoblastomas. A positive tumour cell spectrum ranging from well differentiated cells to poorly differentiated ones was exhibited. Reactive astrocytes in astrocytic gliomas (Fig 5C) were similar to those in retinoblastomas. In control specimens of the normal brain, astrocytes contained GFAP while oligodendrocytes and neurons did not.

**S-100 PROTEIN**

The results with this antibody were basically similar to those with GFAP in retinoblastoma and normal retina, but with negative staining of the Muller's cells. Although the intensity of immunostaining varied, tumour cells expressing S-100 were found in eight of 100 retinoblastomas (8%) in undifferentiated areas (Fig 4D), including two positive for GFAP as well. These cells had the same morphology as well differentiated tumour cells in astrocytic gliomas (Fig 4E) and medulloblastomas (Fig 4F). We also noted that cells expressing S-100 were reactive astrocytes in retinoblastomas (Fig 5B).

**Discussion**

The histogenesis of retinoblastoma has been controversial for more than a century. When applied polyclonal antibodies were detected by a sensitive immunohistochemical method, we found evidence of neuronal and glial differentiation in retinoblastomas.

---

**Figure 2** Differentiated retinoblastoma cells immunostained strongly with neuron specific enolase in Flexner-Wintersteiner rosettes (A) and weakly in Homer-Wright rosettes (arrow, B) (haematoxylin and eosin, bar indicates 100 μm).

**Figure 3** Cells without rosette formation but neuron specific enolase positive in retinoblastoma included well differentiated ones resembling photoreceptors in the outer nuclear layer (A), those tending to form rosettes (B), scattered cells with a few cytoplasmic processes (C), and poorly differentiated small round cells (D) (haematoxylin and eosin, bar indicates 100 μm).
The neuronal and glial markers of NSE, GFAP, and S-100 have been studied critically with various cell types and tumours. NSE, also called gamma-gamma enolase, is normally found in neurons and neuroendocrine cells of the APUD (amine precursor uptake and decarboxylation) system.\textsuperscript{20,21} In this study, we found identical positive staining in normal retina and most of the differentiated retinoblastoma cells. Neurons and their cell processes in the outer and inner nuclear layer, ganglion cells in normal retina, as well as tumour cells forming areas of rosettes in retinoblastomas were NSE positive. Cells forming Flexner-Wintersteiner rosettes were presumed to represent neuronal differentiation.\textsuperscript{15} Other NSE positive cells without apparent rosette formation showed various degrees of differentiation; some of them resembled photoreceptors in the outer nuclear layer, representing considerable differentiation in undifferentiated retinoblastomas. Furthermore, none of the glial cells surrounding blood vessels were immunostained. These findings are in close agreement with those of the previous studies,\textsuperscript{5-9,15,16} indicating that retinoblastoma may derive from neurons, while Molnar and associates observed that rosettes were stained weakly or not at all.\textsuperscript{14} The equivocal findings in the retina and in cells forming Flexner-Wintersteiner rosettes may reflect differences among antibody specificities.

GFAP is widely used as an immunohistochemical marker for astrocytes and neoplastic astrocytes.\textsuperscript{22} S-100 has been shown to be a useful marker for Schwann cells, melanocytes, and glial cells, as well as for their related tumours.\textsuperscript{23} GFAP has been found variously in reactive glial cells,\textsuperscript{7} undifferentiated tumour cells,\textsuperscript{15,16} or has not been detected in retinoblastomas at all.\textsuperscript{12,13} Expression of GFAP has been interpreted as evidence of astroglial histogenesis, differentiation, or both. In human retina, glial cells in the nerve fibre and ganglion cell layers were always stained for GFAP and S-100. In our study, both markers were also detectable in retinoblastoma.

Two crucial questions must be addressed: (1) What are the criteria to identify positive glial cell types? (2) Are the positive glial cells differentiated from a precursor cell in retinoblastoma, or do they originate from a residual glial tissue as a reactive glial proliferation? Based on the cytological features of scanty cytoplasm and short processes, the location of the glial cells within the tumour, and the distance from uninvolved retina, we consider that the positive glial cells separated from normal components of the retina and developed from tumour. Also, the neoplastic glial cells in retinoblastoma resembled well differentiated tumour cells of astrocytic gliomas and medulloblastomas, suggesting an astroglial, rather than a Muller’s cell,\textsuperscript{24} differentiation. However, the majority of the GFAP positive glial cells displayed features of reactive glial cells that were associated with blood vessels. These cells seemed to derive from astrocytes and Muller’s cells in optic nerve and/or normal retina and then proliferate within the tumour. Hence, glial elements in retinoblastomas may represent a glial differentiation along a glial direction and a secondary proliferation of the retinal glial cells in response to tumour growth.

Cells containing GFAP and S-100 in retinoblastoma possessed the morphological attributes of neoplastic cells, but were seldom present in large numbers and lacked the range of stages from mature to anaplastic transition. To our knowledge, there are no well documented reports of an immunopathological study of differentiation of glial elements in retinoblastoma. In addition, the reason that astrocytes preferentially express S-100 in formalin fixed and paraffin embedded materials may be that GFAP is not easily detectable, but often needed for optimal detection in immunohistochemical studies.\textsuperscript{13,15}

The study of medulloblastomas with NSE and GFAP or S-100 has shown components of glia and neuron in the tumour, suggesting the possibility of simultaneous neuronal and glial differentiation. The significance of neoplastic neuronal and glial cells within retinoblastomas is analogous to medulloblastomas to some extent.\textsuperscript{3,25}

Clinically, rosette formation in retinoblastoma is an important indicator for a favourable prognosis.\textsuperscript{26-29} It is evident that optic nerve invasion greatly worsens the prognosis.\textsuperscript{27-29} We classified 100 retinoblastomas according to degree of NSE expression. We found that differentiated tumours without choroidal or optic nerve invasion in patients of younger age (<4 years old) had a significantly higher expression of NSE than did the remaining retinoblastomas. Expression of NSE in differentiated as well as in undifferentiated cells, including photoreceptor-like cells, poorly differentiated cells, or even bipolar-like cells,\textsuperscript{11} may indicate considerable differentiation and may be helpful in predicting benign biological behaviour of the retinoblastoma.

Collectively, a well documented expression of NSE in retinoblastoma favours a neuronal or neuroectodermal lineage. Some glial cells may be incorporated into retinoblastoma from the retina as a secondary response to tumour growth. Tumour cells containing GFAP and S-100 show similar glial differentiation in

\textbf{Table 3  Relations between neuron specific enolase (NSE) expression and clinicopathological features in 100 retinoblastomas}

<table>
<thead>
<tr>
<th>Clinicopathological classification</th>
<th>NE</th>
<th>LE</th>
<th>HE</th>
<th>No</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histopathological type</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Differentiated</td>
<td>2</td>
<td>18</td>
<td>10</td>
<td>30</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Undifferentiated</td>
<td>41</td>
<td>28</td>
<td>1</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Choroidal invasion</td>
<td>13</td>
<td>2</td>
<td>0</td>
<td>15</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>With</td>
<td>31</td>
<td>44</td>
<td>11</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>Without</td>
<td>12</td>
<td>2</td>
<td>0</td>
<td>14</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Optic nerve invasion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With</td>
<td>31</td>
<td>44</td>
<td>11</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>Without</td>
<td>12</td>
<td>2</td>
<td>0</td>
<td>14</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;4</td>
<td>26</td>
<td>37</td>
<td>10</td>
<td>73</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>&gt;4</td>
<td>17</td>
<td>9</td>
<td>1</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>25</td>
<td>22</td>
<td>5</td>
<td>52</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Female</td>
<td>18</td>
<td>24</td>
<td>6</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td><strong>Growth pattern</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endophytum</td>
<td>12</td>
<td>19</td>
<td>3</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>Exophytum</td>
<td>17</td>
<td>20</td>
<td>6</td>
<td>43</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Diffuse infiltration</td>
<td>14</td>
<td>7</td>
<td>2</td>
<td>23</td>
<td></td>
</tr>
</tbody>
</table>

NE=no expression, no positive staining; LE=low expression, distribution of positive cells in less than 50% of the specimen; HE=high expression, distribution of positive cells in more than 50% of the specimen. *Based on the χ² test.
Immunohistochemical evidence of neuronal and glial differentiation in retinoblastoma

Figure 4  Histopathologic comparison of neoplastic cells immunostained with two glial markers of glial fibrillary acidic protein (GFAP) and S-100 protein (S-100) in retinoblastoma, astrocytic glioma, and medulloblastoma. Neoplastic cells stained with GFAP have a round hyperchromatic nucleus, scanty cytoplasm, and a few short thick processes in retinoblastoma (A), resembling those in well differentiated astrocytic glioma (B) and medulloblastoma (C). Neoplastic cells positive for S-100 in retinoblastoma (D) have the same morphology as those in well differentiated astrocytic glioma (E) and medulloblastoma (F) (haematoxylin and eosin, bar indicates 100 μm).

Figure 5  Reactive astrocytes stained with glial fibrillary acidic protein (GFAP) (arrows) and S-100 in retinoblastoma (A and B, respectively) are closely related to blood vessels. These cells are much alike reactive astrocytes stained with GFAP in astrocytic glioma (C), having an oval nucleus, a variable amount of cytoplasm, and long thin multiprocesses (haematoxylin and eosin, bar indicates 100 μm).
retinoblastoma and either type of brain tumour. These results support the notion that retinoblastoma probably arises from primitive bipotential or multipotential cells with partial retention of neuronal and glial characteristics.

Presented in part at 4th National Symposium on Ophthalmic Pathology, Qing Dao, China, 1990.

The authors have no proprietary interest in any subject matter discussed in the article.


Immunohistochemical evidence of neuronal and glial differentiation in retinoblastoma.

K P Xu, S L Liu and C Ni

doi: 10.1136/bjo.79.8.771

Updated information and services can be found at:
http://bjo.bmj.com/content/79/8/771

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/